Evidence map›Paper›PMID 42606175›Full record

ArticleClinical and translational science2026

Omics Biomarkers in Precision Oncology: From the Lens of the ASCPT Biomarkers and Translational Tools and Oncology Communities.

Mai Mehanna, Hardik Mody, Joy C Hsu, Julia Quintanilha, Zachary L Taylor, Angela James, Binita Rajbanshi, Pooja Manchandani, Lakshmi Manasa Chekka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mai MehannaClinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt.ORCID 0000-0002-6895-1246
Hardik ModyClinical Pharmacology, Genentech, South San Francisco, California, USA.
Joy C HsuClinical Pharmacology, Genentech, South San Francisco, California, USA.ORCID 0000-0002-2800-7322
Julia QuintanilhaClinical Development, Foundation Medicine, Inc., Boston, Massachusetts, USA.
Zachary L TaylorDivision of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID 0000-0001-5178-2397
Angela JamesTEQ Enterprises, Evanston, Illinois, USA.
Binita RajbanshiDepartment of Neurology, University of California San Francisco, San Francisco, California, USA.
Pooja ManchandaniClinical Pharmacology Division, Nurix Therapeutics Inc, Brisbane, California, USA.ORCID 0000-0003-0025-5137
Lakshmi Manasa ChekkaDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0001-5996-9180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine. In precision oncology, validating biomarkers is a greater challenge than discovering them. The biomarkers discussed here span a wide evidentiary spectrum, from those endorsed in clinical guidelines to those that remain investigational.

Indexed as

Biomarkers, TumorGenomicsNeoplasmsPrecision MedicineTranslational Research, BiomedicalHumansMedical OncologyMetabolomicsMultiomicsProteomicsBiomarkers, Tumorbiomarkersomicsoncologyprecision medicine

Identifiers

PMID42606175
PMCPMC13479800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.